Latest News from: Roswell Park Comprehensive Cancer Center

Filters close
Newswise: Race and Ethnicity Affect 21-Gene Recurrence Score, Overall Survival in Women with ER+ Breast Cancer
Released: 5-Jun-2023 1:30 PM EDT
Race and Ethnicity Affect 21-Gene Recurrence Score, Overall Survival in Women with ER+ Breast Cancer
Roswell Park Comprehensive Cancer Center

An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer. Based on the expression of 21 cancer-related genes detected in pre-treatment tumor specimens, recurrence score is used routinely in clinical care to identify patients who might benefit from chemotherapy as part of their treatment plan. Scores range from 0-100, with a score of 26 or higher indicating greater risk of recurrence and poorer overall survival.

Newswise: Roswell Park Study is First to Show That Exercise Strengthens Immune System in Multiple Myeloma Patients
Released: 5-Jun-2023 1:20 PM EDT
Roswell Park Study is First to Show That Exercise Strengthens Immune System in Multiple Myeloma Patients
Roswell Park Comprehensive Cancer Center

Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type of white blood cell — multiply out of control. But a clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a non-pharmaceutical method of helping control the disease.

26-Apr-2023 3:05 PM EDT
Roswell Park Nurses Share Their Innovative Practices at Oncology Nursing Society Annual Congress
Roswell Park Comprehensive Cancer Center

Evidence-based practice changes led by nurses from Roswell Park Comprehensive Cancer Center will be highlighted at the 48th annual Oncology Nursing Society (ONS) Congress April 26-30, 2023, in San Antonio, Texas.

Newswise: Roswell Park Investigators Reveal Changes to Immune Status in Patient Tumors After Radiation
Released: 25-Apr-2023 2:30 PM EDT
Roswell Park Investigators Reveal Changes to Immune Status in Patient Tumors After Radiation
Roswell Park Comprehensive Cancer Center

Little is known about how radiation therapy to kill cancer cells affects immune cells and other components of patient tumors. But a study out of Roswell Park Comprehensive Cancer Center is shedding light on that process, providing information that could be key for planning treatment regimens that combine immunotherapy and radiation therapy. The authors outline their findings in a new study in the Journal for ImmunoTherapy of Cancer.

Newswise: New CAR T-Cell Strategy Highly Effective Against Small Cell Lung Cancer in Preclinical Study
Released: 25-Apr-2023 1:30 PM EDT
New CAR T-Cell Strategy Highly Effective Against Small Cell Lung Cancer in Preclinical Study
Roswell Park Comprehensive Cancer Center

A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.

Released: 18-Apr-2023 10:05 AM EDT
FTD/TPI Plus Oxaliplatin Well-Tolerated But Not Broadly Effective as Treatment for Esophageal Cancer
Roswell Park Comprehensive Cancer Center

Research led by Roswell Park's Sarbajit Mukherjee, MD, MS, shows that a new chemotherapy combination — trifluridine/tipiracil (FTD/TPI) and oxaliplatin — is well tolerated and has activity among patients with esophageal cancer.

Newswise: Benefit of Chemotherapy for Patients With Early-Stage Breast Cancer Varies by Tumor Anatomy
Released: 18-Apr-2023 10:05 AM EDT
Benefit of Chemotherapy for Patients With Early-Stage Breast Cancer Varies by Tumor Anatomy
Roswell Park Comprehensive Cancer Center

Based on a large retrospective study, Roswell Park Comprehensive Cancer Center experts that many patients with early-stage breast cancer with rare variant histology, or tumor anatomy, benefit from chemotherapy.

Released: 18-Apr-2023 10:05 AM EDT
From AACR 2023: Roswell Park Researchers Highlight Patient, Survivor Survey on Cannabis
Roswell Park Comprehensive Cancer Center

Results of an anonymous cancer patient and survivor survey conducted by a team from Roswell Park Comprehensive Cancer Center’s Center for Translational Research on Cannabis and Cancer (CTRCC) will be shared at the American Association for Cancer Research 2023 Annual Meeting in Orlando.

Newswise: Vaping CBD Causes More Severe Lung Damage Than Vaping Nicotine, Roswell Park Study Shows
Released: 27-Feb-2023 12:00 PM EST
Vaping CBD Causes More Severe Lung Damage Than Vaping Nicotine, Roswell Park Study Shows
Roswell Park Comprehensive Cancer Center

Vaping cannabidiol (CBD), a compound found in marijuana, leads to more severe lung damage than vaping nicotine, according to a study out of Roswell Park Comprehensive Cancer Center. Until now, research on the health effects of vaping, or using e-cigarettes, has focused almost exclusively on vaping nicotine as opposed to CBD. Previous research has documented the effects of smoking cannabis, but the effects of vaping cannabinoids such as CBD were not previously known.

Newswise: Low Income Linked to High Recurrence Risk, Poorer Survival in Women With ER-Positive Breast Cancer
Released: 21-Feb-2023 1:00 PM EST
Low Income Linked to High Recurrence Risk, Poorer Survival in Women With ER-Positive Breast Cancer
Roswell Park Comprehensive Cancer Center

Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center. The study, “Association of neighborhood-level household income with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer,” appears today in JAMA Network Open.

Newswise: Roswell Park Study: Chronic Opioid Use Reduced by Limiting Prescribed Opioids After Surgery
Released: 5-Jan-2023 2:30 PM EST
Roswell Park Study: Chronic Opioid Use Reduced by Limiting Prescribed Opioids After Surgery
Roswell Park Comprehensive Cancer Center

Research at Roswell Park Comprehensive Cancer Center shows that putting a three-day limit on opioid prescriptions to treat surgical pain after hospital discharge reduces the number of patients who become chronic opioid users without compromising pain relief or recovery. It also reduces the amount of opioids circulating in the community — a grave concern, given that opioids are implicated in 130 overdose deaths in the U.S. every day.

Newswise: Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
Released: 2-Nov-2022 7:25 PM EDT
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
Roswell Park Comprehensive Cancer Center

A targeted therapy for children with high-risk Hodgkin lymphoma significantly reduced relapse rates, a large multicenter clinical trial conducted by the Children’s Oncology Group shows. The study results have been reported in the New England Journal of Medicine.

Released: 1-Nov-2022 10:05 AM EDT
Nation’s Top Cancer Organizations Partner to Endorse Initiative to Increase Lung Cancer Screening in the United States
Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center and Moffitt Cancer Center have partnered with more than 50 other cancer organizations to issue a call to action urging individuals, providers and insurers to increase access to and utilization of low-dose CT scans for those at high risk for lung cancer.

Released: 28-Sep-2022 5:05 PM EDT
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
Roswell Park Comprehensive Cancer Center

T cells engineered to target the cell protein GPRC5D produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study in the New England Journal of Medicine.

Newswise: Roswell Park-Developed Immunotherapy Now Part of Nationwide Study in Kids With Brain Cancer
Released: 7-Jun-2022 2:05 PM EDT
Roswell Park-Developed Immunotherapy Now Part of Nationwide Study in Kids With Brain Cancer
Roswell Park Comprehensive Cancer Center

The immunotherapy SurVaxM is being utilized in a pilot study in children and adolescents with several brain cancer types through a multicenter trial sponsored by the Pediatric Brain Tumor Consortium (PBTC).

Released: 7-Jun-2022 11:00 AM EDT
From ASCO 2022: Brentuximab Vedotin and Chemotherapy an Effective Treatment for Hodgkin Lymphoma
Roswell Park Comprehensive Cancer Center

New research led by Kara Kelly, MD, of Roswell Park Comprehensive Cancer Center and presented today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma. The findings from a phase 3 National Cancer Institute-supported multicenter Children’s Oncology Group clinical trial (NCT 02166463) were presented by first author Sharon Castellino, MD, of Emory University and Children’s Healthcare of Atlanta in an oral abstract session on Friday, June 3.

Newswise: Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia
Released: 6-Jun-2022 11:05 AM EDT
Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia
Roswell Park Comprehensive Cancer Center

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.

Released: 6-Jun-2022 11:00 AM EDT
Roswell Park Researchers Identify Molecular ‘Glue’ That Sticks to and Degrades a Cancer-Causing Protein
Roswell Park Comprehensive Cancer Center

A small molecule discovered and developed by a team of scientists led by Fengzhi Li, PhD, Associate Professor of Oncology in the Department of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center, eliminates human pancreatic and colorectal tumor cells by binding to and degrading DDX5, a powerful cancer-causing protein.

Newswise: Pediatric Lymphoma Trial and Study of FLT3 Inhibitor for Leukemia Highlight Roswell Park Research at ASCO22
Released: 1-Jun-2022 4:30 PM EDT
Pediatric Lymphoma Trial and Study of FLT3 Inhibitor for Leukemia Highlight Roswell Park Research at ASCO22
Roswell Park Comprehensive Cancer Center

Researchers from Roswell Park Comprehensive Cancer Center will present the latest results of clinical trials and insights on cancer treatment and issues affecting patients with cancer, including the financial burdens induced by cancer treatment, at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place both online and in-person in Chicago, Illinois, from June 3 to 7.



close
0.14698